Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 88Breast Neoplasms 49Prostatic Neoplasms 43Squamous Cell Carcinoma of Head and Neck 34Lung Neoplasms 24Stomach Neoplasms 19Neoplasms 19Neoplasm Metastasis 17Head and Neck Neoplasms 17Parkinson Disease 4, Autosomal Dominant Lewy Body 14Urinary Bladder Neoplasms 13Carcinoma, Transitional Cell 11Triple Negative Breast Neoplasms 10Ovarian Neoplasms 8Endometrial Neoplasms 8Carcinoma, Squamous Cell 8Adenocarcinoma 8Non-Muscle Invasive Bladder Neoplasms 7HER2-positive Breast Cancer 7Prostatic Neoplasms, Castration-Resistant 6Melanoma 6Carcinoma 6Small Cell Lung Carcinoma 5Nasopharyngeal Carcinoma 5Esophageal Squamous Cell Carcinoma 5Esophageal Neoplasms 5Advanced Solid Tumors 5Uterine Cervical Neoplasms 4Sarcoma 4Oropharyngeal Neoplasms 4

Interventions

acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1Nivolumab 1Leuprolide 1Goserelin 1Docetaxel 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hormone Sensitive Prostate Cancer × Docetaxel × 1 year × Clear all
NCT04126070 2026-05-27

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
47 enrolled 16 charts
Genitourinary

Hormone Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡